Siouxland high schoolers learn about welding
SOUTH SIOUX CITY, Neb. (KCAU) — On Wednesday, students from around Siouxland gathered in South Sioux City to get a glimpse of what it's like to earn a living under a welding hood.
'Western Welding Academy, we're traveling around the country to 30-plus high schools in 60 days teaching the kids the importance of the blue collar trades' said Quacy Wilson with the Blue Collar Tour.
Several high schoolers were given a hands-on demonstration by certified welders.
'It's super important to let these kids know that college is not the only option out there, that the trades are super important and they're the backbone of our country,' Wilson said. 'It's our job at Western Welding Academy to build a better generation.'
New autism center to open in South Sioux City
Wilson also said that welding is for any student who thinks college may not be the right fit for them and wants to consider the trade industry as a career.
'We're short 400,000 welders as it is,' he said. 'Even if the top welding schools in the country gradate with a thousand kids a year. we would never fill the supply we need. They're very important. We are sponsored by Build Submarines ,which is a department of the Navy. They're trying to build two submarines a year, and they don't have the workers to do it.'
One student from South Sioux City said he is planning on going into the trade business when he is out of high school, as he was inspired by his mother.
'She started welding and I mean, she's the only person I look up to,' student Cesar Luvya Marquez said. 'It's what I'm going to start doing.'
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Insider predicts which New York Jets stars receive contract extensions, including Sauce Gardner
The New York Jets are a team in transition led by first-year head coach Aaron Glenn and general manager Darren Mougey. With a roster centered around a young core of Garrett Wilson, Breece Hall and Sauce Gardner, only a few may receive contract extensions from the new regime. Asked to weigh in on the situation, Albert Breer of Sports Illustrated said he thinks Gardner and Wilson would receive real consideration for extensions right now and both deals could get done. However, a new deal for Hall isn't nearly as likely. Advertisement Related: New York Jets' Allen lazard's stance on playing for Pittsburgh Steelers, Aaron Rodgers 'If I had to guess, Sauce Gardner and Garrett Wilson would be considered for extensions now—and I do think there's a chance at least Gardner and maybe Wilson still get done. With Breece Hall, I think they'd explore it, but signing a back long-term can be tricky. I think with Johnson coming off an injury, they'll probably play it out, knowing they can tag him if he plays to his potential. Sports Illustrated's Albert Breer on future contract extensions for New York Jets stars Both Wilson and Gardner would likely command deals that would make them among the highest-paid NFL players at their respective positions. Even coming off a down year, Gardner could push for $30 million annually given his track record as a two-time All-Pro selection. Garrett Wilson stats (2024): 101 receptions, 1,104 receiving yards, 7 touchdowns While Wilson hasn't received a Pro Bowl selection since being selected with the 10th overall pick in the 2022 NFL Draft, he's delivered three consecutive 1,000-yard seasons despite poor quarterback play. As with cornerbacks, the going rate for No. 1 receivers is now pushing toward $30 million annually. Related: Jets insider sheds light on likely cost of Sauce Gardner contract extension Sauce Gardner stats (2024): 86.9 QB rating, 541 receiving yards, 15.4 yards per completion allowed on 58 targets in 15 games Advertisement Wilson and Gardner have both showcased the talent and durability to be building blocks for the Jets' future. The same can't be said for Hall. While he is coming off consecutive campaigns with over 1,300 scrimmage yards, long-term durability remains a concern and he ranked 39th in true yards per carry (4.0) last season. Furthermore, Hall seemed to be floated in trade rumors this offseason and the Jets at the very least scouted the rookie running back class. While contract extensions seem likely for Gardner and Wilson, Hall will have to prove himself to receive a long-term deal. Related: New York Jets reportedly could target specific position in free agency Related Headlines
Yahoo
4 hours ago
- Yahoo
The Berwyn Group Appoints Adam Wilson as General Manager of Healthcare
Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13, 2025 /PRNewswire/ -- The Berwyn Group (Berwyn), the leader in death audit, locate services and population management, is pleased to announce the hiring of Adam Wilson as General Manager of Healthcare. Wilson brings extensive healthcare industry experience that will further strengthen Berwyn's commitment to excellence and growth. Berwyn offers an end-to-end suite of industry-leading death audit and locate solutions that enable pension and health plan administrators to eliminate costly overpayments, maximize efficiency, meet regulatory requirements, and connect policyholders, participants and beneficiaries to the funds they deserve. More than 2,000 corporate, union and government clients use Berwyn's flagship services, CertiDeath® and CertiCensus®. Wilson joins Berwyn with a distinguished career that spans almost 17 years at UnitedHealthcare, where he held several leadership roles including Vice President of Workforce Planning, Chief of Staff to the COO, and Vice President of Medicare Part D products. "We are thrilled to welcome Adam to the team," said John Bikus, President of Berwyn. "His strategy, proven leadership, and deep industry knowledge will be invaluable as we continue to grow in the healthcare industry." In his new role, Wilson will be responsible for leading Berwyn's strategic expansion into the healthcare market. He will be focusing on aligning Berwyn's solutions to the healthcare payer and provider business cycle needs while also extending the Berwyn reach to healthcare-related supporting partners, vendors, and industry trade groups. "I'm eager to join an organization positioned for rapid growth through industry-leading capabilities," said Wilson. "I look forward to collaborating with the talented team at Berwyn to deliver quick wins, strategic expansion into healthcare, and contribute to the company's continued success." About The Berwyn Group The Berwyn Group is the leader in population data management, offering the industry's most trusted and effective death audit and locate solutions, with an unmatched dedication to innovation, security, and generating outcomes. Acquired by Longevity Holdings in 2023, The Berwyn Group offers an end-to-end suite of industry-leading solutions including CertiDeath® Paragon™, CertiDeath®, CertiCensus®, CertiSearch® and BeneSearch®. Connecting leading-edge technology and data with best-in-class human ingenuity, Berwyn helps bridge the gap between pensions and their participants, insurance companies and their policyholders, third-party administrators and public entities with Medicaid recipients. For more information, visit Media Contact Karlene Gilmore Director of Marketing kgilmore@ View original content: SOURCE The Berwyn Group, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
TELO Rises on Promising Telomir-1 Preclinical Results
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson's disease. In a zebrafish model mimicking Wilson's disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, 'These recent findings establish Telomir-1 as a potent disease-modifying compound in a clinically relevant model of Wilson's disease.' A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year's end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company's position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
